Explore >> Select a destination
|
You are here 
|
www.acc.org | ||
| | | | |
www.cardiobrief.org
|
|
| | | | | A novel drug that dramatically lowers LDL cholesterol and needs to be administered only a few times a year has reached a new milestone. Positive results from a phase II study with the drug, now kno... | |
| | | | |
www.detroitnews.com
|
|
| | | | | Novo Nordisk A/S's blockbuster diabetes drug Ozempic cut patients' risk of dying in a kidney-disease study, the latest research pointing to the medicine's usefulness in a constellation of disorders. | |
| | | | |
blogs.bmj.com
|
|
| | | | | Authors:Miguel Adriano Sanchez-Lastra,Ding Ding,Borja Del Pozo Cruz,Knut Eirik Dalene,Carlos Ayán,Ulf Ekelund,Jakob Tarp. This blog provides a summary of a recently published prospective cohort study exploring joint associations of device-measured physical activity and abdominal obesity with incident cardiovascular disease. Why is this study important? Understanding and managing modifiable risk factors is crucial to reducing the risk [...]Read More... | |
| | | | |
www.vanderbilthealth.org
|
|
| | | |||
